Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.

EKF at InterLab - Algiers, Algeria 2019

The third edition of the exhibition will be held on 25-27 September 2019 at the Palais des Expositions, SAFEX, Algiers, Algeria.

EKF Quo-Test supports improved medical management of diabetic retinopathy patients